Please login to the form below

Not currently logged in
Email:
Password:

Aduro

This page shows the latest Aduro news and features for those working in and with pharma, biotech and healthcare.

Dynavax is ‘deal-ready’ after solid ESMO data; analyst

Dynavax is ‘deal-ready’ after solid ESMO data; analyst

The data from Merck’s study are still maturing, and clinical results from another STING agonist from Novartis/Aduro is due for presentation at the SITC conference in Washington DC next

Latest news

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Among the plethora in the pipeline, Aurigene and BMS are looking at PD-1 inhibitors that can be dosed orally, Novartis, iTeos and Aduro are developing STING agonists that can ... marked more by failures than successes, with a string of candidates

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    825. Aduro / Novartis. Licence and collaboration. Preclinical cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway.

  • Pharma deals in March 2015 Pharma deals in March 2015

    One such example is Novartis which has CAR-T and checkpoint inhibitor programmes and has now added Aduro's STING (Stimulator of Interferon Genes) technology as an additional string to its ... bow. Aduro has a number of preclinical small molecule cyclic

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    1, 000. Aduro BioTech/J&J. Expansion of collaboration. Lung cancer immunotherapies including ADU 214.

  • Pharma deals during October 2014 Pharma deals during October 2014

    on Aduro's novel LADD [live-attenuated double-deleted Listeria monocytogenes strains that have been engineered to induce an innate immune response] immunotherapy platform. ... Now with a headline of $847m, Aduro receives an upfront of $30m with $817m in

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics